Switch Your Mutual Fund or Wait? Build a Review Note First

This time, look beyond the NAV

After reviewing a mutual fund, we often remember only this: “The return was not good this time.” The same question comes up again the following month. A short, dated note lets you compare your earlier thinking with the evidence available today. It is not an automatic buy or sell signal; it is a way to organise information before making a decision.

Start by recording the dates of your documents

Record the full fund name, whether the plan is Direct or Regular, and whether the option is Growth or IDCW. Then note the current factsheet’s “as on” date, the date of the factsheet used at your previous review, and the valuation date on your account statement. The download date and the date of the data may differ. Do not treat them as the same.

Keep the AMC’s official factsheet, Scheme Information Document (SID) and applicable addenda. To find documents, SEBI’s SID directory is a starting point. If information is missing, write “not available”; do not fill the gap with an assumption.

The returns entry: are you comparing like with like?

Write in your note: period ___ to ___; scheme return ___; stated benchmark return ___; calculation basis for both ___. Do not compare a one-year figure with a three-year annualised figure. Put only figures covering the same period and calculation basis from the factsheet side by side.

Record the XIRR from your SIP statement on a separate line. Do not directly turn its comparison with the benchmark’s lump-sum return into a win-or-lose score. A fair investor-level comparison would use the same cash-flow dates and amounts for the benchmark too. If that calculation is unavailable, it is better to clearly record the limitation.

The changes entry: what has actually changed?

Compare the same field in both factsheets: the weight of top holdings, sector allocation or the Riskometer. Record: “Previously ___; now ___; source page ___.” SEBI’s introduction to the Riskometer helps explain risk levels; it does not set a limit on the maximum loss.

Do not jump to a conclusion just because something has changed. Is an explanation from the AMC available? Is the change within the stated mandate? What remains unclear? Write the question separately so you can look for an answer at the next review.

Copy this template to create your review note

• Review date and time remaining until your goal: ___
• Scheme / plan / option; dates of both factsheets: ___
• Scheme and benchmark over the same period; source page: ___
• Observed change in the portfolio or risk, and the evidence: ___
• Current decision, reason, unanswered question and next review: ___

This is a personal note. Do not put your PAN, folio number or account details in a public comment while completing it. Fund information and the reason for your decision are sufficient.

What might a completed entry look like?

Hypothetical example: “The two factsheets show a change in concentration; the reason is not yet clear. I will first read the AMC’s explanation, then review it again in the context of my goal and the rest of my portfolio.” This is an evidence-based next step. It is not advice to hold any actual fund.

Avoid writing only, “I will sell as soon as I recover my purchase price.” If a hypothetical value of ₹100 falls to ₹80, it needs a 25% increase to return to ₹100; a 20% rise would take it only to ₹96. This says nothing about the date or likelihood of recovery.

Complete the note before taking the next step

If a change appears necessary, check tax, exit load and transaction conditions separately. Review these costs too. AMFI’s redemption information and its tax reference (FY 2024–25) are starting points; confirm the rules that apply to your circumstances.

Record the next review date and any material change that would prompt you to review sooner. If needed, use your note as a basis for a discussion with a SEBI-registered Investment Adviser.

This is general education, not personalised buy, sell or hold advice. Historical performance does not guarantee future outcomes.